Search

The outbreak of Monkeypox was declared a public health emergency of worldwide concern by WHO following the (COVID-19) pandemic. The number of reported cases of both suspicion and confirmation has increased in recent years, from over 19,000 between 2000 and 2019 to over 15,600 between 2021 and 2022, and day by day the cases of monkeypox have been reported in 12 member states to three WHO regions. As of May 21, 2022, 92 confirmed cases of monkeypox and 28 suspected cases had been reported to the WHO from more than 12 countries. By the 21st of June 2022, a total of 2677 confirmed cases had been recorded from the UK and other European and non-European countries. According to an extensive literature survey, the total number of registered cases of MPXV was 59,147 between January 2022 to September 14th, 2022, demonstrating that MPXV can spread significantly amongst people and may as a result pose a serious threat to public health with international repercussions. In clade II MPXV virus is currently occurring outside of Africa the WHO reported 25,047 confirmed cases as of August 2nd, 2022. Here, we review current better understanding, and studies on monkeypox, including its history, current scenario, epidemiology, causative agent, symptoms, diagnosis, treatment, limitations, and the new face of monkeypox, its unusual outbreak attributed to the transformation of transmission and also discussed case studies is discussed in this article.

Urtica dioica Linn. (Urticaceae) is a medicinal plant that has shown various therapeutic utilities in folklore medicine along with its use in the treatment of epilepsy. The entire plant has a sensible reservoir of nutritional elements and micronutrients. The purpose of the present study was to investigate the antiepileptic effect of antioxidant potent extract of Urtica dioica root on animal models. Antioxidant activity of various solvent extracts i.e. Petroleum ether extract (PEE), Ethyl acetate extract (EAE), Chloroform extract (CE) and Ethanolic extract (EE) were screened by DPPH radical scavenging assay using Ascorbic acid as the standard. Further the most potent antioxidant extract was subjected to antiepileptic activity against MES and PTZ model. The IC50 values of different Urtica dioica extracts (PEE, CE, EAE, and EE) in antioxidant assay were found to be 167.54 ± 1.97, 134.41 ± 0.82, 88.15 ± 1.39 and 186.38 ± 1.91 μg/ml in DPPH radical scavenging assay, respectively. The EAE has showed the potent antioxidant activity. In experimental study the EAE (100 and 200 mg/kg, p.o) has found to be effective and significant against MES and PTZ induced seizures. The present study also suggested that antioxidant potent extract (EAE) of Urtica dioica root has antiepileptic effect against MES and PTZ induced seizures. However, further research studies will investigate the active component(s) of Urtica dioica responsible for the observed anticonvulsant effects.